RedHill Biopharma Ltd. Files Form 6-K

TL;DR

RHBP filed a 6-K on 7/22, likely with news. Check for details.

AI Summary

RedHill Biopharma Ltd. filed a Form 6-K on July 22, 2024, to report on its activities. The filing incorporates a press release titled "RedHill Biopharma Strengthens," indicating recent developments or strategic moves by the company. The company is based in Tel Aviv, Israel, and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing provides an update on RedHill Biopharma's corporate activities, which could signal strategic shifts or important developments for investors and stakeholders in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As a foreign private issuer in the pharmaceutical sector, RedHill Biopharma faces regulatory, market, and operational risks inherent to the industry and its international status.

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant
• 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (location) — Principal executive offices
• July 2024 (date) — Reporting period
• 001-35773 (other) — Commission File Number

FAQ

Key Financial Figures

• $9.9 million — reement, RedHill received approximately $9.9 million in cash and gained full control over an
• $0.74 million — gained full control over an additional $0.74 million currently held in a restricted account,
• $12.2 million — leading to an increase of approximately $12.2 million in liabilities for RedHill, reflecting
• $2.3 million — alance sheet reduction of approximately $2.3 million. In addition, the Agreement ends all ex

Filing Documents

• zk2431694.htm (6-K) — 25KB
• image00001.jpg (GRAPHIC) — 308KB
• 0001178913-24-002240.txt ( ) — 450KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: July 22, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer Press Release RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia Lien TEL-AVIV, Israel / RALEIGH, NC, July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a Global Termination Agreement with Movantik Acquisition Co., Valinor Pharma, LLC, and HCR Redhill SPV, LLC (the "Agreement"). As a result of the Agreement, RedHill received approximately $9.9 million in cash and gained full control over an additional $0.74 million currently held in a restricted account, leading to an increase of approximately $12.2 million in liabilities for RedHill, reflecting assumed and settled liabilities between the parties, resulting in a net balance sheet reduction of approximately $2.3 million. In addition, the Agreement ends all existing credit ties with the Agreement parties, removes the existing lien against Talicia and restores control over cash collections back to RedHill. Razi Ingber, RedHill's Chief Financial Officer, said: "We are very pleased to reach this smooth conclusion, which strengthens RedHill's cash position and greatly enhances our ability to manage our cash. The Agreement eliminates substantially all encumbrances related to the previous Movantik divestment and Credit Agreements, allowing us to better focus on our R&D and commercial activities and return the Company to a growth mode. This is a new chapter for RedHill." About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious disease

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements, including, but not limited to, statements regarding the intended use of net proceeds from the offering, may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include statements regarding the risk that the Company will not comply with the listing requirements of the Nasdaq Capital Market ("Nasdaq") to remain listed for trading on Nasdaq, the addition of new revenue generating products, out-licensing of the Company's development pipeline assets, timing of opaganib's development for Acute Radiation Syndrome, non-dilutive development funding from RHB-107 and its inclusion in a key platform study. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, market and other conditions, the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication, the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-stu

View Full Filing

View this 6-K filing on SEC EDGAR